Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.36 |
| ▸ | WNT3A | P56704 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 5/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350052 | 0.90 | CTNNB1 (0.41) | SLC6A4CTNNB1WNT3APIK3CAPIK3CG | |
| SCHEMBL2199769 | 0.82 | SLC6A4 (0.38) | SLC6A4CTNNB1WNT3APIK3CAPIK3CG | |
| SCHEMBL7698498 | 0.81 | CYP3A4 (0.54) | SLC6A4CTNNB1WNT3ACYP1A2CYP3A4 | |
| SCHEMBL26696493 | 0.79 | KIF11 (0.37) | SLC6A4CTNNB1WNT3ACYP19A1FAAH | |
| SCHEMBL22657885 | 0.75 | FAAH (0.45) | SLC6A4CTNNB1WNT3ACYP1A2PIK3CA | |
| SCHEMBL8763946 | 0.73 | ALOX15 (0.35) | SLC6A4 | |
| SCHEMBL2537768 | 0.73 | CYP19A1 (0.43) | SLC6A4CTNNB1WNT3APIK3CAPIK3CG | |
| SCHEMBL26026103 | 0.73 | NOS2 (0.41) | CTNNB1WNT3APIK3CAPIK3CGNPC1 | |
| SCHEMBL15435392 | 0.73 | CTNNB1 (0.43) | SLC6A4CTNNB1WNT3ACYP1A2CYP3A4 | |
| SCHEMBL15151309 | 0.72 | CTNNB1 (0.41) | SLC6A4CTNNB1WNT3APIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9314455-B2 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2555754-B1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | VERTEX PHARMA (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20150196539-A1 | Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid | VERTEX PHARMACEUTICALS INCORPORATED | 2015-07-16 | — | — | US | disclosed |
| US-8969574-B2 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140221430-A1 | Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8742122-B2 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130296379-A1 | Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid | VERTEX PHARMACEUTICALS INCORPORATED | 2013-11-07 | — | — | US | disclosed |
| US-8507687-B2 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130085158-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-04 | — | — | US | disclosed |
| EP-2555754-A2 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | Vertex Pharmaceuticals Incorporated (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20110263654-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | VERTEX PHAMACEUTICALS INCORPORATED (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011127290-A2 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296379-A1 | Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC10A1, CEL | SLC6A4 1819/4885CTNNB1 3520/4885WNT3A 2689/4885 |
| US-20150196539-A1 | Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC10A1, CEL | SLC6A4 1819/4885CTNNB1 3520/4885WNT3A 2689/4885 |
| US-20140221430-A1 | Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC10A1, CEL | SLC6A4 1819/4885CTNNB1 3520/4885WNT3A 2689/4885 |
| US-20110263654-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC10A1, CEL | SLC6A4 1819/4885CTNNB1 3520/4885WNT3A 2689/4885 |
| US-20130085158-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC10A1, CEL | SLC6A4 1819/4885CTNNB1 3520/4885WNT3A 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.